“bristol-myers-squibb” Archives

in
Entry Author Date Location
From Yeast, Yumanity Looks to Give Rise to Critical Neuro Drugs 01/26/15 Boston
It Had to be You: Why Roche Was The Lone Suitor For Foundation 01/16/15 Boston
East Coast Biotech Roundup: Foundation, Biogen, Moderna, & Lots More 01/16/15 Boston
Surface Oncology Raises $35M to Develop Cancer Immunotherapies 01/08/15 Boston
Hepatitis C Commercial Game Theory 01/01/15 National
After Spinning Onyx into Gold, Coles Returns to Lead a CNS Startup 12/15/14 Boston
Seattle’s Fred Hutch Taps a Harvard, Merck Vet As New President 11/20/14 Seattle
Celldex Touts Brain Cancer Vaccine Data, Talks FDA Strategy 11/14/14 New York
What Early Looks From ASH Tell Us About Cancer Immunotherapy 11/07/14 National
East Coast Biotech Roundup: Intercept, Idera, Inotek, & More 11/07/14 Boston
East Coast Biotech Roundup: Sarepta, Aegerion, Syros, Aileron & More 10/31/14 Boston
Backed by Gates, Affinivax Ramps up Velcro-like Vaccine Tech 10/30/14 Boston
Try Then Buy? Sutro Deal Could Be Celgene’s Biggest Antibody Bet Yet 10/23/14 New York
East Coast Biotech Roundup: Raze, Retrophin, Alnylam, & More 10/16/14 Boston
What Seattle Needs (Part 3): Working Together to Revitalize Biotech 10/08/14 Seattle
What Seattle Needs (Part 2): Dealing With Amgen’s Upcoming Departure 10/07/14 Seattle
East Coast Biotech Roundup: Intarcia, Atlas, Visterra, & More 10/06/14 Boston
What Seattle Needs (Part 1): “Semi-Successful” Biotech Companies 10/06/14 Seattle
East Coast Biotech Roundup: GliaCure, Civitas, T2, & More 09/29/14 Boston
Blessed By Angels, GliaCure Tests New Alzheimer’s Approach In Humans 09/26/14 Boston
Cempra Milestone Highlights Experimental Antibiotic’s Potential 09/09/14 Raleigh Durham
East Coast Biotech Roundup: Infinity, Merck, Voyager, Ebola, & More 09/05/14 Boston
Merck, Leapfrogging Bristol-Myers, Wins FDA Nod for Cancer Drug 09/04/14 New York
West Coast Biotech Roundup: Mapp Bio, Calico, Alder, VentiRx & More 09/04/14 San Diego
Bristol-Myers Kicks Arthritis Drug Back to Alder, Shares Tumble 09/02/14 Seattle
Exelixis Axes 70% of Workforce as Cancer Drug Flops, Shares Routed 09/02/14 San Francisco
Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis? 08/25/14 San Francisco
East Coast Biotech Roundup: NJ Blues, Genzyme, Amicus, Biogen & More 08/25/14 Boston
Standing on a Ledge Once Again, Amicus Holds Breath for Latest Study 08/11/14 New York
Jounce Taps Merck Vet to Lead Cancer Drug Push 07/10/14 Boston
Page 3 of 12 « previous page · next page »